) recently presented encouraging long-term data from a phase I/II
study on Jakafi, for the treatment of bone marrow fibrosis, at
the 2013 annual meeting of the American Society of Clinical
Oncology (ASCO). Bone marrow fibrosis is a key feature of
Results from the study showed that bone marrow fibrosis
stabilized/improved after 24 and 48 months in most MF patients
treated with Jakafi. The bone marrow fibrosis stabilization was
however not seen in long-term treatment with hydroxyurea.
At the end of 48 months, bone marrow fibrosis stabilized in
56% of the patients and improved in 22% of the patients treated
with Jakafi. The same was 44% and 0% respectively in patients
treated with hydroxyurea.
Meanwhile, bone marrow fibrosis grade worsened in 37% and 25%
of the patients treated with Jakafi at the end of 24 months and
48 months, respectively. Compared to this, bone marrow fibrosis
grade worsened in 65% and 74% of patients treated with
hydroxyurea at the end of 24 months and 48 months,
We note that Jakafi is already approved for the treatment of
patients suffering from intermediate or high-risk myelofibrosis
in the US. Jakafi is also being studied for the treatment of
polycythemia vera, essential thrombocythemia, solid/other
hematologic tumors and pancreatic cancer.
Moreover, Incyte's pipeline also has INCB024360 (advanced
malignancies), INCB28060 (solid tumors) and INCB39110
(myelofibrosis, rheumatoid arthritis, psoriasis) among
Incyte, a biopharmaceutical company, currently carries a Zacks
Rank #4 (Sell). Other biopharma stocks such as
Jazz Pharmaceuticals Public Limited Company
Cubist Pharmaceuticals Inc.
) currently look better positioned. While, Jazz Pharma and
Santarus carry a Zacks Rank #1 (Strong Buy), Cubist Pharma
carries a Zacks Rank #2 (Buy).
CUBIST PHARM (CBST): Free Stock Analysis
INCYTE CORP (INCY): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
To read this article on Zacks.com click here.